Braidwell LP Sells 142,492 Shares of Oruka Therapeutics, Inc. $ORKA

Braidwell LP reduced its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 9.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,382,350 shares of the company’s stock after selling 142,492 shares during the quarter. Braidwell LP owned about 3.33% of Oruka Therapeutics worth $26,583,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Viking Global Investors LP bought a new position in shares of Oruka Therapeutics in the third quarter worth $51,280,000. Avoro Capital Advisors LLC bought a new stake in Oruka Therapeutics during the third quarter valued at $25,640,000. Deep Track Capital LP boosted its stake in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after buying an additional 735,983 shares during the period. Geode Capital Management LLC grew its position in Oruka Therapeutics by 100.6% during the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after buying an additional 354,821 shares in the last quarter. Finally, Franklin Resources Inc. grew its position in Oruka Therapeutics by 40.6% during the second quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock worth $11,355,000 after buying an additional 292,421 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on ORKA. BTIG Research reaffirmed a “buy” rating and issued a $73.00 price target on shares of Oruka Therapeutics in a report on Friday. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, March 8th. UBS Group started coverage on shares of Oruka Therapeutics in a research report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus lifted their target price on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research report on Friday. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.67.

Oruka Therapeutics Stock Up 25.0%

Shares of ORKA stock opened at $40.00 on Friday. The business has a 50-day moving average price of $32.92 and a two-hundred day moving average price of $27.59. Oruka Therapeutics, Inc. has a 12-month low of $5.49 and a 12-month high of $41.19. The firm has a market cap of $1.94 billion, a P/E ratio of -21.51 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. As a group, research analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider owned 34,018 shares of the company’s stock, valued at $1,101,162.66. This represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 21,000 shares of company stock valued at $663,530. Insiders own 24.69% of the company’s stock.

More Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.